motor neuron disorder
motor neuron disorder
Explore linked clinical trials. Standard reference: MONDO:0020128403 results · Page 1 of 17
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Interfacing With NeuroTechnology to Expand Neural Throughput (INTENT) | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Infarction, Muscular Disorders, Atrophic, Necrosis, Neurologic Manifestations, Nutritional and Metabolic Diseases, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, TDP-43 proteinopathy, amyotrophic lateral sclerosis, brain disorder, brain infarction, brain ischemia, brain stem infarction, cardiovascular disorder, central nervous system disorder, cerebrovascular disorder, hereditary disease, injury, ischemic disease, metabolic disease, motor neuron disorder, muscle tissue disorder, muscular dystrophy, musculoskeletal system disorder, nervous system disorder, nervous system injury, neurodegenerative disease, neuromuscular disease, palsy, progressive muscular atrophy, proteostasis deficiencies, quadriplegia, spinal cord disorder, spinal cord injury, spinal muscular atrophy, stroke disorder, vascular disorder | Recruiting | Not applicable | 2026-10-09 | NCT07521930 | |
| Self-Efficacy Enhancement Among Online Support Group of Primary Caregivers of Children With Neuro Muscular Dystrophy | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Duchenne muscular dystrophy, Muscular Disorders, Atrophic, X-linked disease, central nervous system disorder, hereditary disease, motor neuron disorder, muscle tissue disorder, muscular dystrophy, musculoskeletal system disorder, nervous system disorder, neurodegenerative disease, neuromuscular disease, spinal cord disorder, spinal muscular atrophy | Active, not recruiting | Not applicable | 2026-10-09 | NCT07356063 | |
| A Study to Assess the Safety, Tolerability, and Pharmacology of Darifenacin in Patients With ALS | Nutritional and Metabolic Diseases, TDP-43 proteinopathy, amyotrophic lateral sclerosis, central nervous system disorder, metabolic disease, motor neuron disorder, nervous system disorder, neurodegenerative disease, neuromuscular disease, proteostasis deficiencies, spinal cord disorder | Recruiting | Phase 2 | 2026-10-09 | NCT06249867 | |
| PhiCube for Bilateral Upper Limb Neuromotor and Cognitive Rehabilitation in Adults | Cognition Disorders, Cognitive Dysfunction, Mild Cognitive Impairment, Neurologic Manifestations, Nutritional and Metabolic Diseases, Paresis, Parkinson disease, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, TDP-43 proteinopathy, Upper Extremity Paresis, amyotrophic lateral sclerosis, basal ganglia disorder, brain disorder, cardiovascular disorder, central nervous system disorder, cerebrovascular disorder, cognitive disorder, injury, metabolic disease, motor neuron disorder, movement disorder, nervous system disorder, nervous system injury, neurodegenerative disease, neuromuscular disease, parkinsonian disorder, proteostasis deficiencies, psychiatric disorder, spinal cord disorder, spinal cord injury, stroke disorder, synucleinopathy, vascular disorder | Not yet recruiting | Not applicable | 2026-10-08 | NCT07865260 | |
| Do Video Recordings of Multidisciplinary Clinics Improve Quality of Life for People With ALS and Their Caregivers? | Nutritional and Metabolic Diseases, TDP-43 proteinopathy, amyotrophic lateral sclerosis, central nervous system disorder, metabolic disease, motor neuron disorder, nervous system disorder, neurodegenerative disease, neuromuscular disease, proteostasis deficiencies, spinal cord disorder | Recruiting | Not applicable | 2026-10-08 | NCT07454733 | |
| A Study to Assess the Safety, Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of Intravenous Administration of ARGX-119 in Pediatric Participants Aged 5 to Less Than 18 Years With Spinal Muscular Atrophy | central nervous system disorder, motor neuron disorder, nervous system disorder, neurodegenerative disease, neuromuscular disease, spinal cord disorder, spinal muscular atrophy | Recruiting | Phase 2 | 2026-10-08 | NCT07287982 | |
| A Study of Risdiplam in Infants With Genetically Diagnosed and Presymptomatic Spinal Muscular Atrophy | central nervous system disorder, motor neuron disorder, nervous system disorder, neurodegenerative disease, neuromuscular disease, spinal cord disorder, spinal muscular atrophy | Active, not recruiting | Phase 2 | 2026-10-08 | NCT03779334 | |
| Electrical Impedance Myography: Natural History Studies inNeuromuscular Disorders and Healthy Volunteers | motor neuron disorder, nervous system disorder, neurodegenerative disease, neuromuscular disease | Recruiting | Not applicable | 2026-10-08 | NCT01900132 | |
| ARTFL LEFFTDS Longitudinal Frontotemporal Lobar Degeneration (ALLFTD) | Frontotemporal Lobar Degeneration, Neurologic Manifestations, Nutritional and Metabolic Diseases, Ocular Motility Disorders, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, TDP-43 proteinopathy, amyotrophic lateral sclerosis, basal ganglia disorder, brain disorder, central nervous system disorder, cognitive disorder, corticobasal degeneration disorder, cranial nerve neuropathy, dementia, eye disorder, frontotemporal dementia, frontotemporal dementia with motor neuron disease, metabolic disease, motor neuron disorder, movement disorder, nervous system disorder, neurodegenerative disease, neuromuscular disease, ophthalmoplegia, palsy, proteostasis deficiencies, psychiatric disorder, spinal cord disorder, tauopathy | Recruiting | Not stated | 2026-10-07 | NCT04363684 | |
| Pridopidine Phase 3 Study to Evaluate Efficacy and Safety in ALS | Nutritional and Metabolic Diseases, TDP-43 proteinopathy, amyotrophic lateral sclerosis, central nervous system disorder, metabolic disease, motor neuron disorder, nervous system disorder, neurodegenerative disease, neuromuscular disease, proteostasis deficiencies, spinal cord disorder | Recruiting | Phase 3 | 2026-10-06 | NCT07322003 | |
| Trial on the Biological and Clinical Effects of Acetyl-L-carnitine in ALS | Nutritional and Metabolic Diseases, TDP-43 proteinopathy, amyotrophic lateral sclerosis, central nervous system disorder, metabolic disease, motor neuron disorder, nervous system disorder, neurodegenerative disease, neuromuscular disease, proteostasis deficiencies, spinal cord disorder | Recruiting | Phase 2 / Phase 3 | 2026-10-06 | NCT06126315 | |
| A Study to Learn About the Investigational Drug Rinzimetostat (ORIC-944) in Patients With mCRPC Who Were Previously Treated With Abiraterone Acetate (Himalayas-1) | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Disease Attributes, Genital Diseases, Kennedy disease, Male Urogenital Diseases, Neoplasms by Site, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Recurrence, Urogenital Diseases, Urogenital Neoplasms, X-linked disease, central nervous system disorder, hereditary disease, inherited neurodegenerative disorder, male reproductive organ cancer, male reproductive system disorder, motor neuron disorder, neoplasm, nervous system disorder, neurodegenerative disease, neuromuscular disease, prostate cancer, prostate disorder, spinal cord disorder, spinal muscular atrophy | Recruiting | Phase 3 | 2026-10-05 | NCT07723248 | |
| The NO-ALS Study: A Trial of Nicotinamide/Pterostilbene Supplement in ALS. | Nutritional and Metabolic Diseases, TDP-43 proteinopathy, amyotrophic lateral sclerosis, central nervous system disorder, metabolic disease, motor neuron disorder, nervous system disorder, neurodegenerative disease, neuromuscular disease, proteostasis deficiencies, spinal cord disorder | Active, not recruiting | Not applicable | 2026-10-05 | NCT04562831 | |
| A Study to Learn About the Safety of BIIB147 and Its Effects in Adults With Amyotrophic Lateral Sclerosis (ALS) | Nutritional and Metabolic Diseases, TDP-43 proteinopathy, amyotrophic lateral sclerosis, central nervous system disorder, metabolic disease, motor neuron disorder, nervous system disorder, neurodegenerative disease, neuromuscular disease, proteostasis deficiencies, spinal cord disorder | Not yet recruiting | Phase 1 / Phase 2 | 2026-10-02 | NCT07855211 | |
| A Study of Risdiplam in Participants With Type I and Type II Spinal Muscle Atrophy (SMA) | central nervous system disorder, motor neuron disorder, nervous system disorder, neurodegenerative disease, neuromuscular disease, spinal cord disorder, spinal muscular atrophy | Recruiting | Not stated | 2026-10-02 | NCT07531719 | |
| A Study to Learn About Salanersen's (BIIB115) Effects on Movement and Its Safety in Participants Aged 15 to 60 Years With Spinal Muscular Atrophy (SMA) Who Are Either New to SMA Treatment or Were Previously Treated With Risdiplam | central nervous system disorder, motor neuron disorder, nervous system disorder, neurodegenerative disease, neuromuscular disease, spinal cord disorder, spinal muscular atrophy | Recruiting | Phase 3 | 2026-10-02 | NCT07444476 | |
| A Trial to Learn How Safe AZD9750 is and How Well it Works in People With Metastatic Prostate Cancer When Given With or Without Other Anticancer Drugs | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Genital Diseases, Kennedy disease, Male Urogenital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, X-linked disease, central nervous system disorder, hereditary disease, inherited neurodegenerative disorder, male reproductive organ cancer, male reproductive system disorder, motor neuron disorder, neoplasm, nervous system disorder, neurodegenerative disease, neuromuscular disease, prostate cancer, prostate disorder, spinal cord disorder, spinal muscular atrophy | Active, not recruiting | Phase 1 / Phase 2 | 2026-10-02 | NCT07336446 | |
| A Study to Evaluate How Apitegromab Works in Subjects Who Are Less Than 2 Years Old and Have Spinal Muscular Atrophy | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Muscular Atrophy, Spinal, Type II, Neurologic Manifestations, Neuromuscular Manifestations, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, Spinal Muscular Atrophies of Childhood, central nervous system disorder, hereditary disease, inherited neurodegenerative disorder, motor neuron disorder, nervous system disorder, neurodegenerative disease, neuromuscular disease, proximal spinal muscular atrophy, spinal cord disorder, spinal muscular atrophy, spinal muscular atrophy, type III | Recruiting | Phase 2 | 2026-10-02 | NCT07047144 | |
| TP04HN106 in the Treatment of Patients With Amyotrophic Lateral Sclerosis | Nutritional and Metabolic Diseases, TDP-43 proteinopathy, amyotrophic lateral sclerosis, central nervous system disorder, metabolic disease, motor neuron disorder, nervous system disorder, neurodegenerative disease, neuromuscular disease, proteostasis deficiencies, spinal cord disorder | Recruiting | Phase 1 / Phase 2 | 2026-10-02 | NCT06726577 | |
| A Study Evaluating the Effectiveness and Safety of Risdiplam Administered as an Early Intervention in Pediatric Participants With Spinal Muscular Atrophy After Gene Therapy | central nervous system disorder, motor neuron disorder, nervous system disorder, neurodegenerative disease, neuromuscular disease, spinal cord disorder, spinal muscular atrophy | Recruiting | Phase 4 | 2026-10-02 | NCT05861986 | |
| Metabolism and Nutrition in MND | Body Weight, Body Weight Changes, Nutritional and Metabolic Diseases, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, TDP-43 proteinopathy, Weight Loss, amyotrophic lateral sclerosis, central nervous system disorder, metabolic disease, motor neuron disorder, nervous system disorder, neurodegenerative disease, neuromuscular disease, proteostasis deficiencies, spinal cord disorder | Not yet recruiting | Not stated | 2026-10-01 | NCT07851714 | |
| Acamprosate in C9orf72 Hexanucleotide Repeat Expansion Amyotrophic Lateral Sclerosis (ACALS) | Nutritional and Metabolic Diseases, TDP-43 proteinopathy, amyotrophic lateral sclerosis, central nervous system disorder, frontotemporal dementia with motor neuron disease, metabolic disease, motor neuron disorder, nervous system disorder, neurodegenerative disease, neuromuscular disease, proteostasis deficiencies, spinal cord disorder | Recruiting | Phase 1 | 2026-10-01 | NCT07204977 | |
| MindEx: A Novel, Multifocal, Cognitive Brain-Machine Interface System | Infarction, Necrosis, Neurologic Manifestations, Nutritional and Metabolic Diseases, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, TDP-43 proteinopathy, amyotrophic lateral sclerosis, brain disorder, brain infarction, brain ischemia, brain stem infarction, cardiovascular disorder, central nervous system disorder, cerebrovascular disorder, injury, ischemic disease, metabolic disease, motor neuron disorder, nervous system disorder, nervous system injury, neurodegenerative disease, neuromuscular disease, palsy, proteostasis deficiencies, quadriplegia, spinal cord disorder, spinal cord injury, stroke disorder, vascular disorder | Recruiting | Not applicable | 2026-10-01 | NCT05936619 | |
| A Registry of Cases of Spinal Muscular Atrophy | central nervous system disorder, motor neuron disorder, nervous system disorder, neurodegenerative disease, neuromuscular disease, spinal cord disorder, spinal muscular atrophy | Recruiting | Not stated | 2026-09-30 | NCT07805278 | |
| A Study to Compare the Efficacy and Safety of BMS-986365 Versus the Investigator's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Genital Diseases, Kennedy disease, Male Urogenital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, X-linked disease, central nervous system disorder, hereditary disease, inherited neurodegenerative disorder, male reproductive organ cancer, male reproductive system disorder, motor neuron disorder, neoplasm, nervous system disorder, neurodegenerative disease, neuromuscular disease, prostate cancer, prostate disorder, spinal cord disorder, spinal muscular atrophy | Active, not recruiting | Phase 3 | 2026-09-30 | NCT06764485 |